RxDoctor Payments DataLook up a doctor →

Lisa Davidson, MD

Neurology · Mankato, MNNPI 1184603193

Payments from drug & device makers

$113,077in general payments, 2019–2025

Across 244 payments — averaging $463.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$76K
  • Teva Pharmaceuticals USA, Inc.$36K
  • Sun Pharmaceutical Industries Inc.$182
  • UCB, Inc.$133
  • Tanabe Pharma America, Inc.$111
  • Biogen$102
  • plus $1K from 43 others

What the payments were for

  • Consulting fees$1,1501%
  • Speaking & faculty fees$101,33790%
  • Travel & lodging$6,6136%
  • Food & beverage$3,9353%
  • Education$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$113,077 in reported general payments places this provider in the 85th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$465,152
Medicare patients
284
Services billed
52,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rebif RebidoseInterferon Beta-1a/Albumin26$250,896
RebifInterferon Beta-1a/Albumin18$217,952
CopaxoneGlatiramer Acetate12$70,100
UbrelvyUbrogepant60$65,400
Nurtec OdtRimegepant Sulfate30$27,261
Emgality PenGalcanezumab-Gnlm22$17,900
Dalfampridine ErDalfampridine11$13,030
Rufinamide15$8,969
FingolimodFingolimod Hcl12$6,988
Sumatriptan Succinate53$6,114
Gabapentin123$3,709
Lacosamide22$3,007
Ropinirole Hcl144$2,815
Pregabalin74$2,677
Propranolol Hcl ErPropranolol Hcl31$2,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$43$217,95218 claims
Teva Pharmaceuticals USA, Inc.Copaxone$35,617$70,10012 claims
AbbVieUbrelvy$75,539$65,40060 claims
PfizerNurtec Odt$13$27,26130 claims
Upsher-smith Laboratories LLCTopiramate$39$49859 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 434 neurology providers in Minnesota.

Other neurology in Mankato

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →